

Accepted Manuscript

Title: Lung cancer epigenetics: from knowledge to applications

Authors: Michaël Duruisseaux, Manel Esteller

PII: S1044-579X(17)30166-9

DOI: <http://dx.doi.org/10.1016/j.semcancer.2017.09.005>

Reference: YSCBI 1382

To appear in: *Seminars in Cancer Biology*

Received date: 20-6-2017

Revised date: 12-9-2017

Accepted date: 13-9-2017



Please cite this article as: Duruisseaux Michaël, Esteller Manel. Lung cancer epigenetics: from knowledge to applications. *Seminars in Cancer Biology* <http://dx.doi.org/10.1016/j.semcancer.2017.09.005>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Lung cancer epigenetics: from knowledge to applications

Authors names and affiliations:

Michaël Duruisseaux ^{a,b}, Manel Esteller ^{a,c,d}

^a Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), 08908 L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.

^b Department of Respiratory Medicine, Hôpital Louis-Pradel, Hospices civils de Lyon, 28 avenue du Doyen Lépine, 69677 Lyon cedex, France.

^c Institució Catalana de Recerca i Estudis Avançats (ICREA), 08010 Barcelona, Catalonia, Spain

^d Department of Physiological Sciences II, School of Medicine, University of Barcelona, 08036 Barcelona, Catalonia, Spain

Correspondence to:

Dr Manel Esteller

Email contact : mesteller@idibell.cat

Address: Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), Gran Via de L'Hospitalet de Llobregat 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Catalonia, Spain.

Phone Number: (+34) 93 260 71 40 / 93 260 7253

Fax Number: (+34) 93 260 72 19

Email contact for Michaël Duruisseaux: michaelduruisseaux@gmail.com

ABSTRACT:

Lung cancer is the leading cause of cancer-related mortality worldwide. Advances in our understanding of the genomics of lung cancer have led to substantial progress in the treatment of specific molecular subsets. Immunotherapy also emerges as a major breakthrough in lung cancer treatment. However, challenges remain as a consensual approach for early lung cancer detection remains elusive while primary or secondary drug resistance eventually leads to treatment failure in all patients with advanced disease. Furthermore, a large portion of patients are still treated with conventional chemotherapy that is only modestly effective. The last two decades have seen exponential developments in the epigenetic

Download English Version:

<https://daneshyari.com/en/article/8361741>

Download Persian Version:

<https://daneshyari.com/article/8361741>

[Daneshyari.com](https://daneshyari.com)